Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POL7080 in Non-CF Bronchiectasis Exacerbation
NCT02096315Phase 2Terminated
- Sponsor
- Polyphor
- Start
- Dec 2013
- Primary completion
- Nov 2015
- Modality
- Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of murepavadin in Non-cystic fibrosis bronchiectasis (NCFB), Pseudomonas aeruginosa infection, sponsored by Polyphor. Started Dec 2013; status: terminated.
02
Drugs
murepavadin
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02096315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096315.